Company Description
Third Harmonic Bio, Inc., a biopharmaceutical company, focuses on the development of the medicine for the treatment of dermal, respiratory, and gastrointestinal inflammatory diseases.
The company develops oral small-molecule inhibitors of KIT, a cell surface receptor that serves as the master regulator of mast cell function and survival.
It also develops THB335, an oral small molecule KIT inhibitor for the treatment of mast cell-mediated inflammatory diseases, respiratory, and gastrointestinal conditions.
It has a license agreement with Novartis Pharma AG. The company was formerly known as Project IGE, Inc. and changed its name to Third Harmonic Bio, Inc. in June 2019.
Third Harmonic Bio, Inc. was incorporated in 2019 and is headquartered in San Francisco, California.
| Country | United States |
| Founded | 2019 |
| IPO Date | Sep 15, 2022 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 53 |
| CEO | Natalie Holles |
Contact Details
Address: 1700 Montgomery Street, Suite 210 San Francisco, California 94111 United States | |
| Phone | 209 727 2457 |
| Website | thirdharmonicbio.com |
Stock Details
| Ticker Symbol | THRD |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $17.00 |
| CIK Code | 0001923840 |
| CUSIP Number | 88427A107 |
| ISIN Number | US88427A1079 |
| Employer ID | 83-4553503 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Natalie C. Holles | Chief Executive Officer and Director |
| Christopher M. Murphy | Chief Financial and Business Officer |
| Jennifer Dittman | Chief Operating Officer |
| Julie Person | Chief Administrative Officer |
| Steven P. Sweeney | Senior Vice President of Development Operations |
| Dr. Edward R. Conner M.D. | Chief Medical Officer |
| Dennis Dean Ph.D. | Chief Non-Clinical Development Officer |
| Ommer Chohan | Treasurer and Secretary |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jul 31, 2025 | 8-K | Current Report |
| Jul 31, 2025 | S-8 POS | Securities to be offered to employees in employee benefit plans, post-effective amendments |
| Jul 31, 2025 | S-8 POS | Securities to be offered to employees in employee benefit plans, post-effective amendments |
| Jul 31, 2025 | S-8 POS | Securities to be offered to employees in employee benefit plans, post-effective amendments |
| Jul 31, 2025 | S-8 POS | Securities to be offered to employees in employee benefit plans, post-effective amendments |
| Jul 31, 2025 | POS AM | Post-Effective amendments for registration statement |
| Jul 31, 2025 | 25 | Filing |
| Jul 21, 2025 | 8-K | Current Report |
| Jun 12, 2025 | 8-K | Current Report |
| Jun 11, 2025 | 8-K | Current Report |